La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

SinoMab BioScience Salute del bilancio

Salute finanziaria criteri di controllo 1/6

SinoMab BioScience ha un patrimonio netto totale di CN¥295.6M e un debito totale di CN¥391.4M, che porta il suo rapporto debito/patrimonio netto a 132.4%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥847.8M e CN¥552.2M.

Informazioni chiave

153.0%

Rapporto debito/patrimonio netto

CN¥423.78m

Debito

Indice di copertura degli interessi	n/a
Contanti	CN¥194.86m
Patrimonio netto	CN¥276.93m
Totale passività	CN¥564.87m
Totale attività	CN¥841.80m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year

Mar 04

What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition

Jan 28

Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?

Jan 01

Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term

Nov 30

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥270.2M ) di 3681 superano le sue passività a breve termine ( CN¥172.6M ).

Passività a lungo termine: Le attività a breve termine di 3681 ( CN¥270.2M ) non coprono le sue passività a lungo termine ( CN¥379.6M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 52.1% ) di 3681 è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di 3681 è aumentato da 36.5% a 132.4% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 3681 ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: 3681 ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 15.6 % ogni anno

SinoMab BioScience Salute del bilancio

Salute finanziaria criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

First half 2024 earnings released: CN¥0.085 loss per share (vs CN¥0.13 loss in 1H 2023)

SinoMab BioScience Limited to Report First Half, 2024 Results on Aug 19, 2024

SinoMab BioScience Limited Announces First Patient Dosed in A Phase 1b Clinical Trial of SM17 in China

SinoMab BioScience Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings released: CN¥0.24 loss per share (vs CN¥0.29 loss in FY 2022)

SinoMab BioScience Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China

SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China

Sinomab Bioscience Limited Announces IND Application for SM03 (Suciraslimab) for the Treatment of Alzheimer's Disease Accepted by NMPA CDE

Sinomab Bioscience Limited announces Change of Non-Executive Directors

New minor risk - Financial position

SinoMab BioScience Limited to Report First Half, 2023 Results on Aug 21, 2023

Sinomab Bioscience Limited Announces IND Application for SM17 Accepted by NMPA CDE

SinoMab BioScience Limited Announces Filing and Acceptance of Investigational New Drug Application for SM17 by the Center for Drug Evaluation of the National Medical Products Administration of China

SinoMab BioScience Limited Announces Executive Changes

Less than half of directors are independent

Sinomab Bioscience Limited Announces Enrollment in Phase I First-In-Human (FIH) Clinical Trial

Sinomab Bioscience Limited Announces Enrollment in Phase I First-In-Human (FIH) Clinical Trial

Sinomab Bioscience Limited Announces IND Approval for SN1011 by National Medical Products Administration of China

SinoMab BioScience Limited Announces First Healthy Subject Dosed in A Phase I Clinical Trial of SM17 in the U.S

SinoMab BioScience Limited Announces Retirement of Mr. Senlin LIU as Non-Executive Director

Less than half of directors are independent

Sinomab Bioscience Limited Announces an Investigational New Drug Application for SN1011

SinoMab BioScience Limited, Annual General Meeting, Jun 13, 2022

SinoMab BioScience Limited Provides an Update in Relation to Group's Key Products, SM17

SinoMab BioScience Limited Files Investigational New Drug Application SN1011

SinoMab BioScience Limited Announces SM03 Completion of Enrollment in Phase III Clinical Trial in China

SinoMab BioScience Limited to Report Fiscal Year 2020 Results on Mar 22, 2021

Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year

What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition

New 90-day high: HK$4.70

Sinomab Bioscience Limited Announces First Healthy Subject Dosed in A Phase I Clinical Trial of SN1011 in China

Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?

SinoMab BioScience Limited announced that it expects to receive HKD 100 million in funding from Haiyao International Group Limited

New 90-day high: HK$3.60

SinoMab BioScience Limited Announces Executive Changes

Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term

New 90-day low: HK$3.15

SinoMab BioScience Limited to Report First Half, 2020 Results on Aug 24, 2020

New 90-day low - HK$3.39

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane